| Literature DB >> 24144949 |
Romualdo Barroso-Sousa1, Iuri A Santana, Laura Testa, Débora de Melo Gagliato, Max S Mano.
Abstract
In recent years, a number of new molecules - commonly known as biological therapies - have been approved or are in late stages of regulatory evaluation for the treatment of advanced breast cancer. These innovative compounds have improved treatment efficacy and have probably contributed to the increase in survival length observed in some breast cancer subtypes. However, these agents are not deprived of toxicity, which can impair quality of life and may occasionally be life-threatening. In this article, we reviewed the most common toxicities associated with these drugs and provided a number of practical recommendations on their optimal clinical management.Entities:
Keywords: ABC; AE; Adverse events; Bevacizumab; Breast cancer; CT; EGFR; Everolimus; FDA; Food and Drug Administration; HER2; LVEF; Lapatinib; Pertuzumab; QoL; RCC; T-DM1; Trastuzumab; Trastuzumab emtansine; Trastuzumab-emtansine; VEGF; advanced breast cancer; adverse event; computed tomography; epidermal growth factor receptor; human epidermal growth factor receptor type 2; left ventricular ejection fraction; mTOR; quality of life; renal cell cancer; the mammalian target of rapamycin; vascular endothelial growth factor
Mesh：
Substances：
Year: 2013 PMID： 24144949 DOI： 10.1016/j.breast.2013.09.009
Source DB: PubMed Journal: Breast ISSN： 0960-9776 Impact factor: 4.380